1. Scrip
  2. >>Therapy Areas

CNS Licensing Trends: Volume Falls, Values Rise

 
• By Lucie Ellis-Taitt

According to a new analysis from Datamonitor Healthcare, the volume of deals in the CNS space has fallen since 2012 but the overall value of alliances is increasing, particularly when it comes to up-front payments for potential Alzheimer's therapies.

Human brain
2016 saw fewer CNS alliances overall but deal values are on the rise • Source: Shutterstock

Licensing deals involving drugs for central nervous system conditions were worth more in 2016 than previous years, although there are fewer agreements being signed in this disease space. One of the most lucrative CNS pacts since 2012 was AbbVie Inc. and Google-funded start-up Calico Life Sciences LLC's arrangement for new treatments targeting Alzheimer's and other diseases related to aging.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.